6 Lifestyle Trends for Professionals in 2026, Ranked by the Evidence

By Tom Morgan · Updated October 1, 2026 · ~13 min read

The evidence behind lifestyle trends runs almost exactly opposite to the money behind them. The best-supported ideas (protect sleep, lift weights twice a week, work fewer hours) are close to free. The worst-supported (NAD+ supplements, continuous glucose monitors for healthy people) are where the marketing budgets sit. That second half is my reading of the pattern, not a measured fact, but the evidence below is why I hold it.

The money is real. The Global Wellness Institute (GWI) puts the global wellness economy at $6.8 trillion in 2024, up 7.9% in a year and double its 2013 size, with a forecast of about $9.8 trillion by 2029. I recomputed the implied growth rate from those two endpoints: (9.8 ÷ 6.8)^(1/5) − 1 ≈ 7.6% a year, which matches GWI’s own figure. [1]

Market size, though, says nothing about whether any single product works. A $6.8 trillion category contains exercise physiology and expensive placebo under the same label. This article sorts the six biggest professional-lifestyle trends by what the research shows, and tells you what to do about each.

Quick answer: which lifestyle trends have the best evidence in 2026?
In order of strength: (1) strength training and adequate sleep, (2) income-preserving shorter workweeks, (3) mental-health apps for mild-to-moderate symptoms, (4) wearables as a sleep-habit mirror, (5) sustainability claims, (6) digital nomadism, which is a logistics decision rather than a health intervention. NAD+ supplements, the most heavily marketed part of “longevity,” rank last.

The ranking at a glance

Evidence key used in the source list: T1 = peer-reviewed study, meta-analysis, or official document; T2 = large survey or industry dataset; T3 = press or secondary coverage. “My analysis” marks my own interpretation.

1. Healthy aging: the basics are strong, the supplements are not

“Longevity” is one label covering two very different evidence bases, and most coverage blurs them.

The part that holds up

A 2022 systematic review and meta-analysis in the British Journal of Sports Medicine pooled 16 prospective cohort studies. Muscle-strengthening activity was associated with a 10–17% lower risk of death from any cause, and of cardiovascular disease, total cancer, diabetes and lung cancer. The maximum benefit appeared at roughly 30–60 minutes per week, and the curve for higher volumes was unclear. Combining strength and aerobic work looked better than either alone. [2]

For most people, 30–60 minutes a week means two short sessions.

The honest limits: these were observational studies, mostly American, with self-reported activity. Healthy-user bias is a live risk, because people who lift also tend to sleep, eat, and see doctors differently. Mortality is too slow an endpoint to randomize at scale, so this evidence will probably stay observational plus mechanistic. That is still a far better foundation than anything the supplement market has.

Sleep belongs in the same tier. The American Academy of Sleep Medicine and the Sleep Research Society’s consensus statement recommends that adults regularly sleep seven or more hours a night. [3]

The part that does not

A 2026 systematic review of NAD+ augmentation covered 33 human intervention studies (28 randomized) and 80 rodent studies. Oral precursors such as NMN and NR reliably raise NAD+-related biomarkers in humans and are generally well tolerated in the short term. Evidence for clinically meaningful anti-aging or wellness benefit, though, was described as heterogeneous and inconclusive, and the authors note that animal results do not reliably predict human efficacy. [4]

My position: don’t buy NMN for longevity. A raised blood marker is not an outcome, and I found no adequately powered human trial with mortality or disease-onset endpoints. If the supplement budget goes to a coach or a gym membership, it buys more.

Blue Zones are contested, so don’t use them as proof. Researcher Saul Newman argues that extreme-age records in some longevity hotspots reflect clerical errors and pension fraud. The demographers who defined the Blue Zones say they verified ages against multiple independent documents such as birth and baptism records, and critics reply that a wrong birth record gets copied consistently across documents. [5][6] Newman’s central paper has been described as a preprint. The movement-heavy habits Blue Zones celebrate duplicate what the exercise literature already supports, so nothing is lost by setting the debate aside.

2. The shorter workweek: the measurable core of “slow living”

“Slow living” has no operational definition in the research literature. Single-tasking and digital sabbaths have not been tested at scale. What has been tested, at scale and with control groups, is reducing working hours without cutting pay.

The best study is Fan, Schor, Kelly and Gu in Nature Human Behaviour (2025): 2,896 employees at 141 organizations across Australia, Canada, Ireland, New Zealand, the UK and the US ran a six-month, income-preserving four-day week. Burnout, job satisfaction, mental health and physical health all improved, a pattern not seen at 12 control companies. [7] Press coverage reports an average reduction of about five working hours a week and attributes the gains to less fatigue, fewer sleep problems and greater work ability. [8]

The detail most coverage skips is what the firms did to make it work. Participating organizations had roughly eight weeks to restructure workflow before the trial began, and reporting on the study points to removing unproductive tasks, meetings in particular, as the way output was held steady. [9][10] The intervention was not “give people Fridays.” It was “cut work, then cut hours.”

Limits to keep in view:

• All 141 companies volunteered, and the sample leans toward smaller firms in English-speaking countries. [10][11]
• Outcomes were surveys, not objective measures.
• Only 12 control firms were compared.
• Press reports that more than 90% of firms kept the schedule come from the authors’ own statements to journalists; I did not find an independent audit.

Don’t conflate this with the 2022 UK pilot. The UK trial (61 companies, roughly 2,900 employees) was run by Autonomy and 4 Day Week Global and reported in a non-peer-reviewed report. [12] The headcount is nearly identical to the 2025 paper’s 2,896, which makes the two easy to mix up. They are different studies with different evidence quality.

My judgment: for anyone who manages people, this is the best-evidenced workplace wellbeing intervention I found. For an individual employee, the lever is not willpower. It is negotiating the mechanism the trial firms used: audit and remove recurring low-value meetings before asking for fewer hours.

3. Mental-health apps: real, small, and not a substitute for care

Large meta-analyses agree on the shape of the evidence. Linardon and colleagues’ 2019 analysis of 66 RCTs found apps beat control conditions for depressive symptoms (g = 0.28), generalized anxiety (g = 0.30) and stress (g = 0.35), but found no significant benefit for panic or post-traumatic stress symptoms, though those rested on only 3 and 4 trials. [13] The 2024 update, covering 176 RCTs, concluded that apps have small but significant effects on depression and generalized anxiety, with stronger effects when the app was designed to target depression specifically. [14][15] In conventional effect-size terms, 0.2 is “small” and 0.5 “moderate,” so these results sit at the small end. A separate meta-analysis of 69 trials found small, acute effects on perceived stress, larger when the comparison group got nothing. [16]

The pattern across all three: the better the control condition, the smaller the effect.

AI therapy: one promising trial, one fair critique

The first randomized trial of a fully generative-AI therapy chatbot (Therabot, Dartmouth, NEJM AI, March 2025) enrolled 210 adults with depression, generalized anxiety or high risk for eating disorders. After a four-week intervention, symptoms fell by about 51% (depression), 31% (anxiety), and 19% (eating-disorder concerns) in press reporting of the results. [17] A published letter in the same journal argued that the conclusions are weakened by the use of a waitlist control, the absence of independent evaluation, and the misapplication of a measure of therapeutic alliance built for human therapists. [18]

I weigh the critique heavily. A waitlist comparison tells you the bot beat doing nothing, which is the easiest bar in the literature. It does not tell you it beats a self-help workbook or a human clinician.

One more correction to the conventional wisdom: Woebot, a frequently recommended name, is gone. Woebot Health closed its consumer app on June 30, 2025; its founder cited the cost of FDA authorization and the lack of a regulatory path for large language models. [19]

My judgment: use an app for a defined problem (stress, low mood, sleep) and pick one built for that problem. Treat it as a bridge to care. If symptoms persist or interfere with work, sleep, or relationships, see a clinician. And note that the evidence for panic and PTSD is thin enough that an app should not be your plan for either.

4. Wearables and CGMs: a mirror, not a treatment

Adoption has plateaued, so the real question has changed

Rock Health’s 2025 survey of 8,000 census-matched US adults, fielded in December 2025, found that 46% own a wearable, up from 13% in 2015. Growth in first-time owners has slowed. Among owners, 83% wear a device five or more days a week, and 48% still use the first device they bought. [20] The old Pew figure of 21% for “regularly use a smartwatch or fitness tracker” is from 2019 and measures something different (regular use, not ownership), so the two numbers cannot be read as a growth curve. [21]

My analysis: wearables stopped being an adoption story. The live question is what people do with the data, because the buying decision has already been made by nearly half of adults.

How accurate is the sleep data?

A peer-reviewed single-night study put 35 healthy adults aged 20–50 on polysomnography (PSG, the clinical gold standard) while they wore an Oura Ring Gen3, a Fitbit Sense 2, and an Apple Watch Series 8. All three devices detected sleep versus wake with at least 95% sensitivity. Stage-level accuracy was a different story. Sensitivity for deep sleep was 79.5% for Oura, 61.7% for Fitbit, and 50.5% for Apple Watch, and the Apple Watch overestimated light sleep by about 45 minutes while underestimating deep sleep by about 43. [22]

The caveats: one night, 35 people, no sleep disorders. A separate Brigham and Women’s study reported a similar device ordering, but it was funded by Oura, so I treat it as supporting, not independent, evidence. [23]

Practical reading: trust time asleep and consistency; distrust stage scores. There is also a documented downside. Sleep clinicians coined the term orthosomnia in 2017 for patients whose anxiety about their tracker data made their sleep worse. [24]

Continuous glucose monitors for people without diabetes

This is the weakest-evidenced piece of mainstream biohacking, and it is now sold over the counter. The picture across systematic reviews:

• A 2026 meta-analysis concluded that CGM may lower mean glucose and improve adherence in non-diabetic people. The benefit was clearest in prediabetes, while healthy people mainly gained educational value. [25]
• A 2024 meta-analysis of RCTs found favorable but modest effects of CGM feedback on glycemic control in adults with and without diabetes. [26]
• A 2026 PROSPERO-registered review of participant-visible CGM in adults without diabetes concluded that psychosocial evidence was insufficient to establish benefit or exclude harm. [27]

My judgment: one sensor cycle to see how your own meals behave is a defensible experiment. Month-after-month wear by a healthy person lacks outcome evidence, and the one review of psychological effects could not rule out harm.

5. Sustainable consumption: the market signal is real, and the law just changed

The McKinsey/NielsenIQ study tracked US consumer-packaged-goods sales from 2017 to mid-2022. Products making ESG-related claims grew 28% cumulatively versus 20% for products making none, and accounted for 56% of category growth. Established products with claims beat their claim-free counterparts in 68% of categories; newer products did so in only 32%. [28]

Two corrections to how this is usually told:

• It is not “1.7x faster.” That figure is a garbling of a McKinsey spokesperson’s “170 basis points” comment. [29] My own compounding of 28% and 20% over five years gives about 5.1% versus 3.7% a year, a gap near 1.4 points. The difference of 170 basis points likely reflects the averaging method, but either way it is nowhere near a multiple.
• It is a correlation about claims, not about truth. The study looked at sales of products carrying claims; it did not assess whether the claims were accurate. [30]

The real news: EU law on green claims applies as of last week

Directive (EU) 2024/825, the Empowering Consumers for the Green Transition Directive, became applicable on 27 September 2026. It treats as unfair practices generic environmental claims such as “eco-friendly” or “green” unless recognized excellent environmental performance can be shown, offset-based “climate neutral” product claims, and self-created sustainability labels. [31][32]

This is frequently confused with the separate Green Claims Directive proposal (which would have required verification of claims before use). That proposal has been stalled since June 2025; sources differ on whether to call it paused or withdrawn. The consumer-claims directive is adopted law either way. [32][33]

My judgment: for brands selling into the EU, auditing every generic environmental adjective is now a legal task, not a branding preference. For shoppers, ignore adjectives and look for specific, checkable claims and third-party certification, while checking what a given certification actually covers.

6. Digital nomadism: still growing, but the mix has changed

The popular story is that nomadism has peaked. The data points somewhere more specific.

MBO Partners’ 2025 State of Independence study counts 18.5 million American digital nomads, up 2.2% from the prior year, up 153% since 2019, and about 12% of the US workforce. After explosive growth in 2020–2022, the report describes only modest increases in 2023–2025. [34]

The notable shift is who the nomads are: nomads with traditional jobs grew 10% to 11.2 million, while independent nomads (freelancers and owners) fell 7% to 7.3 million. [34] Of employed nomads, 13% say their employer doesn’t know they are nomadic, and 81% of nomads overall report high satisfaction with their work and lifestyle. [35] That satisfaction figure comes from a survey of people who still identify as nomads, so people who tried it and quit are not in it.

Visas: tightening in places, diverging overall

Several flagship programs raised their income bars in 2026 because the thresholds are pegged to wages. Portugal’s D8 now requires €3,680 a month, four times the €920 minimum wage. Croatia’s threshold is €3,622.50, up from €3,295 before March 2026. [36] One 2026 tracker characterizes the year as divergence rather than uniform tightening. [37] Published counts of nomad-visa countries range from roughly 37 to more than 60 depending on how a program is defined, so be wary of any single “number of countries” claim. [37][38]

My judgment: the right frame is not “peak nomad.” It is that the growth moved to employees, which means employer policy and tax residency now matter more than the visa. Get written approval from your employer before moving, ask payroll and a tax adviser about residency thresholds (the trackers I reviewed list 183 days as common) and corporate tax exposure, and check visa thresholds again each spring, because wage-linked numbers change. This is not tax advice.

Where sources disagree

What to do: seven rules that change a decision

1. Fix your wake time for four weeks before buying any tracker. Use the tracker only for time asleep and consistency. If you still average under seven hours and haven’t moved your bedtime, the problem is behavior, not data. If tracking makes you anxious about sleep, stop.
2. Schedule two strength sessions a week, 30–60 minutes in total. That is where the meta-analytic benefit peaked.
3. Choose a mental-health app built for your specific problem, and don’t rely on one for panic or PTSD. Persistent symptoms mean a clinician, not a different app.
4. If you manage a team, redesign before you cut. Run an eight-week workflow and meeting audit first, which mirrors the trial’s preparation phase, then pilot reduced hours with pay unchanged.
5. Healthy and curious about glucose? One CGM sensor cycle, not a subscription. If you have prediabetes, do it with a clinician.
6. Redirect the NAD+ budget. It buys more as a coach, a gym membership, or better sleeping conditions.
7. Before moving abroad for work, get your employer’s permission in writing and confirm tax residency. If you sell into the EU, audit every generic environmental claim now.

Frequently asked questions

Which lifestyle trend has the strongest evidence?
Strength training combined with adequate sleep. A meta-analysis of 16 cohort studies links 30–60 minutes of weekly muscle-strengthening to roughly 10–20% lower mortality risk, and sleep consensus guidance recommends seven or more hours. The evidence is observational. [2][3]

Are wearables accurate for sleep?
For sleep versus wake, yes (at least 95% sensitivity in one 35-person PSG study). For sleep stages, much less so: deep-sleep sensitivity ranged from 50.5% to 79.5% across three devices. [22]

Do mental-health apps work?
They produce small but statistically significant improvements for depression, generalized anxiety, and stress across large meta-analyses. Effects are smaller against better control conditions, and the few available trials for panic and PTSD showed no significant benefit. [13][14][16]

Is a four-day week proven to reduce burnout?
The strongest evidence, a 2025 Nature Human Behaviour study of 141 volunteer organizations, found reduced burnout with no pay cut compared with 12 control firms. Volunteer participation and self-reported outcomes limit how far it generalizes. [7][10]

Is digital nomadism still growing?
Slowly. MBO Partners counted 18.5 million American nomads in 2025, up 2.2%, with growth concentrated among employees rather than freelancers. [34]

Are NMN supplements worth buying?
Not for longevity. Human trials show they raise NAD+ biomarkers, but a 2026 systematic review found the clinical anti-aging evidence inconclusive. [4]

Is “eco-friendly” still legal on products sold in the EU?
Not as a standalone claim. Since 27 September 2026, generic environmental claims are prohibited unless recognized excellent environmental performance can be demonstrated. [31][32]

How this was checked. I checked each figure against the publisher, journal or agency page where I could open it, and I traced the main claims in the earlier version of this post back to their original sources. I could not open the full text of several papers, so some numbers come from abstracts or press coverage; those are marked T3 in the source list. I ran no tests myself, and nothing here is proprietary data. The only calculations that are mine are the 7.6% growth recomputation and the 5.1% versus 3.7% annualization, and the inputs are shown above. Vendor claims (device makers, supplement sellers, app companies) were not treated as evidence unless an independent study supported them. This is general information, not medical, legal, tax or financial advice.

Update note. This article replaces an April 2026 version. Figures corrected: US digital nomads are 18.5 million per MBO Partners (the earlier text said 35 million); McKinsey’s $1.8 trillion wellness figure is global (the 2025 edition puts the global market at about $2 trillion and the US at over $500 billion), not US-only; the ESG growth gap is 28% versus 20% rather than “1.7x”; and the EU green-claims rule that applies is Directive 2024/825, not the stalled Green Claims Directive.

Sources

Tier tags: T1 peer-reviewed or official · T2 large survey or industry dataset · T3 press or secondary coverage.

1. Global Wellness Institute (2025). 2025 Global Wellness Economy Monitor. globalwellnessinstitute.org · T2
2. Momma H. et al. (2022). Muscle-strengthening activities and mortality in major non-communicable diseases: systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine. PMC9209691 · T1
3. Watson N.F. et al. (2015). Recommended amount of sleep for a healthy adult (AASM/SRS consensus). Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.4758 · T1
4. NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence (2026). ScienceDirect · T1
5. ABC News Australia (July 2026). The battle for the Blue Zones. abc.net.au · T3
6. Science (2024). Do “blue zones,” supposed havens of longevity, rest on shaky science? science.org · T3
7. Fan W., Schor J.B., Kelly O., Gu G. (2025). Work time reduction via a 4-day workweek finds improvements in workers’ well-being. Nature Human Behaviour 9, 2153–2168. nature.com · T1
8. The Register (July 2025). Four-day weeks and the Nature Human Behaviour trial. theregister.com · T3
9. Forbes (July 2025). New study: switching to a 4-day workweek reduces burnout. forbes.com · T3
10. The People Space (2025). The 4-day week works, but only if you change the work. thepeoplespace.com · T3
11. PsyPost (2025). Large-scale trial finds four-day workweek improves employee well-being. psypost.org · T3
12. Autonomy (2023). The results are in: the UK’s four-day week pilot. autonomy.work · T2
13. Linardon J. et al. (2019). The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of RCTs. World Psychiatry 18(3). PubMed 31496095 · T1
14. Linardon J. et al. (2024). Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety: a meta-analysis of 176 RCTs. World Psychiatry 23(1). Wiley · T1
15. The Mental Elf (2024). Apps for depression and anxiety: big new meta-analysis supports effectiveness. nationalelfservice.net · T3
16. Efficacy of mental health smartphone apps on stress levels: a meta-analysis of randomised controlled trials (2024). Health Psychology Review. tandfonline.com · T1
17. MIT Technology Review (March 2025). The first trial of generative AI therapy shows it might help with depression (reporting Heinz et al., NEJM AI). technologyreview.com · T3
18. A Letter about “Randomized Trial of a Generative AI Chatbot for Mental Health Treatment.” NEJM AI. ai.nejm.org · T1
19. Psychology.com (2026). Woebot review: consumer app retired June 30, 2025. psychology.com · T3
20. Rock Health (2025). Insights on wearables and connected devices from the 2025 Consumer Adoption Survey (n = 8,000; fielded Dec 1–23, 2025). rockhealth.com · T2
21. Pew Research Center (2020). About one-in-five Americans use a smart watch or fitness tracker. pewresearch.org · T2
22. Accuracy of three commercial wearable devices for sleep tracking in healthy adults (2024). Sensors. doi:10.3390/s24206532 · T1
23. Sleep Review (2024). Oura Ring, Apple Watch and Fitbit tested against PSG (Oura-funded Brigham and Women’s study). sleepreviewmag.com · T3
24. Baron K.G. et al. (2017). Orthosomnia: are some patients taking the quantified self too far? Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.6472 · T1
25. Continuous glucose monitoring in non-diabetic populations: systematic review of observational and interventional studies with meta-analysis (2026). Springer · T1
26. The efficacy of using continuous glucose monitoring as a behaviour change tool in populations with and without diabetes: systematic review and meta-analysis of RCTs (2024). Int J Behav Nutr Phys Act. Springer · T1
27. Behavioral and psychosocial effects of participant-visible continuous glucose monitoring in adults without diabetes: a systematic review (2026). PMC13609687 · T1
28. McKinsey & Company / NielsenIQ (2023). Consumers care about sustainability, and back it up with their wallets. mckinsey.com · T2
29. FoodNavigator-USA (2023). Sustainability sells: McKinsey, NielsenIQ research shows link between ESG claims, higher growth. foodnavigator-usa.com · T3
30. Carbon Credit Markets (2023). New research by NielsenIQ & McKinsey: consumers care and are in fact buying sustainable goods. carboncreditmarkets.com · T3
31. European Union. Directive (EU) 2024/825 on empowering consumers for the green transition. EUR-Lex · T1
32. Obsidian Regulatory Intelligence (Sept 2026). ECGT green claims rules apply from September 27, 2026. obsidianri.com · T3
33. Tappr (2026). Green Claims Directive: status, timeline and what happens next. usetappr.com · T3
34. MBO Partners (2025). Digital Nomads Trends Report, State of Independence. mbopartners.com · T2
35. MBO Partners (2025). Corporate digital nomad policy: best practices and guidelines. mbopartners.com · T2
36. Genki Guide for Digital Nomads (2026). Digital nomad visas: all countries compared. guide. genki.world · T3 (verify thresholds with official sources before applying)
37. Job4Travelers (Sept 2026). Digital Nomad Visa Tracker 2026. job4travelers.com · T3
38. Silicon Valley Times (2026). Best digital nomad visas in 2026. siliconvalleytime.com · T3
39. McKinsey & Company (2025). The Future of Wellness trends survey 2025 (9,000+ consumers in China, Germany, the UK and the US). mckinsey.com · T2

About the author. Tom Morgan is a content strategist (300+ content audits across B2B SaaS and tech, US/EU markets). This article summarizes published research; it is not based on proprietary data, and the author is not a clinician. Corrections: contact@futurenow.click
No sponsorships · No affiliate links · No paid placements.